By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

VAXIMM 

Elisabethenstrasse 3

Basel      Switzerland
Phone: n/a Fax: n/a


SEARCH JOBS



Segment
Vaccines





Company News
VAXIMM Announces Data From Phase I Trial In Glioblastoma With Oral T-Cell Immunotherapy VXM01 To Be Presented At ASCO 2017 Annual Meeting 5/18/2017 12:45:53 PM
VAXIMM Announces Collaboration With Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) To Evaluate Combination Of VXM01 With Avelumab In Glioblastoma And Colorectal Cancer In Phase I/II Clinical Studies 5/9/2017 8:51:30 AM
VAXIMM Announces Presentations At Upcoming Industry And Scientific Events 5/3/2017 11:45:26 AM
VAXIMM To Present Preclinical Data On Three Novel Oral T-Cell Immunotherapies At AACR Annual Meeting 2017 3/30/2017 9:52:46 AM
VAXIMM Presents Preclinical Data On Three Novel Oral T-Cell Cancer Immunotherapies At EORTC-NCI-AACR Symposium 12/1/2016 3:22:07 PM
VAXIMM Appoints Dr. Matthias Schroff As Chief Executive Officer 9/1/2016 2:09:24 PM
VAXIMM Initiates Phase 1 Translational Study In Glioblastoma With Oral T-Cell Immunotherapy, VXM01 7/12/2016 9:57:28 AM
ASCO2016: VAXIMM Presents Data From Phase I Trial In Pancreatic Cancer With Oral T-Cell Immunotherapy VXM01 At ASCO 2016 Annual Meeting 6/6/2016 2:41:25 PM
VAXIMM Initiates Phase 2a Study In Advanced Colorectal Cancer With Oral T-Cell Vaccine VXM01 5/4/2016 9:31:18 AM
VAXIMM Reports Positive Follow-On Data From Oral Cancer Vaccine Trial 12/4/2014 1:21:39 PM
12
//-->